Bristol Myers Squibb (BMY) Accumulated Expenses (2009 - 2019)
Bristol Myers Squibb (BMY) reported Accumulated Expenses of $5.9 billion for Q1 2019, up 5.3% year-over-year from $5.6 billion in Q1 2018, and down 9.75% on a QoQ basis from $6.5 billion in Q4 2018.
Bristol Myers Squibb (BMY) has 11 years of Accumulated Expenses data on file, last reported at $5.9 billion in Q1 2019.
- Quarterly Accumulated Expenses rose 5.3% year-over-year to $5.9 billion in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $5.9 billion (up 5.3% YoY) and the FY2018 annual result came in at $6.5 billion, up 7.9% from the prior year.
- Accumulated Expenses slipped to $5.9 billion in Q1 2019 per BMY's latest filing, from $6.5 billion in the prior quarter.
- Across five years, Accumulated Expenses topped out at $6.5 billion in Q4 2018 and bottomed at $1.8 billion in Q1 2015.
- The 5-year median for Accumulated Expenses is $5.1 billion (2017), against an average of $4.8 billion.
- The widest annual swing landed in 2015, when Accumulated Expenses retreated 10.32%; it then soared 140.7% in 2016.
- Tracing BMY's Accumulated Expenses over 5 years: stood at $4.7 billion in 2015, then gained by 11.25% to $5.3 billion in 2016, then gained by 14.1% to $6.0 billion in 2017, then increased by 7.9% to $6.5 billion in 2018, then dropped by 9.75% to $5.9 billion in 2019.
- Per Business Quant, the three latest BMY Accumulated Expenses figures stand at $5.9 billion (Q1 2019), $6.5 billion (Q4 2018), and $5.9 billion (Q3 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 5.86 Bn |
| Dec 31, 2018 | 6.49 Bn |
| Sep 30, 2018 | 5.85 Bn |
| Jun 30, 2018 | 5.83 Bn |
| Mar 31, 2018 | 5.56 Bn |
| Dec 31, 2017 | 6.01 Bn |
| Sep 30, 2017 | 5.42 Bn |
| Jun 30, 2017 | 5.13 Bn |
| Mar 31, 2017 | 4.78 Bn |
| Dec 31, 2016 | 5.27 Bn |
| Sep 30, 2016 | 4.96 Bn |
| Jun 30, 2016 | 4.88 Bn |
| Mar 31, 2016 | 4.31 Bn |
| Dec 31, 2015 | 4.74 Bn |
| Sep 30, 2015 | 2.33 Bn |
| Jun 30, 2015 | 2.10 Bn |
| Mar 31, 2015 | 1.79 Bn |
| Dec 31, 2014 | 2.46 Bn |
| Sep 30, 2014 | 2.29 Bn |
| Jun 30, 2014 | 2.20 Bn |
| Mar 31, 2014 | 2.00 Bn |
| Dec 31, 2013 | 2.15 Bn |
| Sep 30, 2013 | 2.28 Bn |
| Jun 30, 2013 | 2.42 Bn |
| Mar 31, 2013 | 2.38 Bn |
| Dec 31, 2012 | 2.57 Bn |
| Sep 30, 2012 | 2.76 Bn |
| Jun 30, 2012 | 2.47 Bn |
| Mar 31, 2012 | 2.57 Bn |
| Dec 31, 2011 | 571.00 Mn |
| Sep 30, 2011 | 2.70 Bn |
| Jun 30, 2011 | 2.83 Bn |
| Mar 31, 2011 | 2.66 Bn |
| Dec 31, 2010 | 108.00 Mn |
| Dec 31, 2009 | 2.79 Bn |
| Sep 30, 2009 | 2.99 Bn |
| Jun 30, 2009 | 2.55 Bn |